• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Vi­tal Ther­a­pies evis­cer­at­ed as PhI­II dis­as­ter forces it to dis­card sole as­set

7 years ago
R&D

Atre­ca banks a $125M mega-round as it builds a pipeline of an­ti­bod­ies for can­cer and pon­ders IPO tim­ing

7 years ago
Financing

Bris­tol-My­ers claims the lead in a race to de­vel­op a TYK2 drug, hop­ing to dis­rupt a huge mar­ket for ...

7 years ago
R&D

Take­da shut­ter­ing Chica­go com­plex with 1,000 staffers in lead-up to Shire merg­er

7 years ago
Deals

Gilead, Gala­pa­gos re­port com­pet­i­tive num­bers for first big PhI­II read­out for fil­go­tinib in rheuma­toid arthri­tis

7 years ago
R&D

Pfiz­er, Mer­ck KGaA tout PhI­II suc­cess for Baven­cio; Im­mun­sanT gets a new in­vest­ment from JDRF

7 years ago
News Briefing

A Mar­tin Shkre­li wannabe de­fends a big spike in drug price and earns a Twit­ter lash­ing from the FDA's com­mish

7 years ago
Pharma

GSK-backed sci­en­tif­ic team at UCSF says they found the im­mor­tal­i­ty switch in can­cer cells — and know how to turn it ...

7 years ago
Discovery

Mer­ck her­alds a rare Big Phar­ma suc­cess for an­tibi­ot­ic PhI­II, but it’s al­so a cau­tion­ary tale about the mar­ket

7 years ago
R&D
Pharma

Join­ing the ex­o­dus at Gilead, CMO An­drew Cheng makes the switch to biotech CEO — trig­ger­ing a cross-coun­try move ...

7 years ago
People

No­var­tis makes it of­fi­cial: Al­con is mov­ing its HQ from Texas to Gene­va ahead of a spin­off

7 years ago
Pharma

Fo­cus­ing on the tu­mor mi­croen­vi­ron­ment, On­coRe­sponse gar­ners $40 mil­lion for the next stage of the R&D jour­ney

7 years ago
Financing
Startups

An­a­lyst of­fers Am­gen a boost for its ri­val an­ti-BC­MA BiTE, blem­ish­ing GSK as well as CAR-T ri­vals Cel­gene and ...

7 years ago
Cell/Gene Tx

Acor­da shares crater af­ter ap­peals court dash­es re­main­ing hopes for sal­vaging Ampyra patents — gener­ics loom

7 years ago
Pharma

The Broad wins an­oth­er — per­haps fi­nal — bat­tle in the war over Feng Zhang's CRISPR patents

7 years ago
People
Pharma

NHS re­fus­es to cov­er Ocre­vus for pri­ma­ry pro­gres­sive MS; OxStem taps vet­er­an drug hunter Georg Ter­stap­pen as CSO

7 years ago
News Briefing

SEC ac­cus­es biotech bil­lion­aire Phillip Frost of join­ing a 'pump-and-dump' scheme that net­ted $27M

7 years ago
People

Chi­nese phar­ma pow­er­house Han­soh joins fledg­ling biotechs in the Hong Kong IPO line

7 years ago
Financing
China

Am­i­cus chief John Crow­ley is snubbed at the FDA on his lat­est pitch for quick drug re­view. He'll be back, but an­a­lyst ...

7 years ago
Pharma

A star can­cer sci­en­tist failed to dis­close in­dus­try pay­ments over the years — does that mat­ter so much?

7 years ago
People

Tra­di­tion­al­ists at Take­da spark a fam­i­ly feud with CEO Christophe We­ber over his $62B Shire takeover deal

7 years ago
Deals

Re­volv­ing door be­tween in­dus­try and FDA con­tin­ues to spin

7 years ago
People
Pharma

Cir­cled by ri­val phar­ma gi­ants and a biotech pow­er­house, Ko­di­ak asks for a $100M-plus IPO for new eye drug

7 years ago
Financing

The pain won't stop. GSK ends the week with a slap­down on its Nu­cala ap­pli­ca­tion for COPD

7 years ago
Pharma
First page Previous page 9979989991000100110021003 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.